Riga

• A dose ranging study to investigate efficacy and safety of subcutaneous TOUR006 compared with placebo in participants 18 to 80 years of age … Recruiting
  2024-514801-69-00 4 2025-04-02 Thyroid Eye Disease
• A prospective randomized open-label phase II clinical study evaluating the efficacy and safety of zoledronic acid addition to standard thera … Recruiting
  2024-519446-67-00 4 2025-03-06 Glioblastoma
• A study to assess the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia Recruiting
  2024-515451-38-00 5 2025-02-27 Primary Immune thrombocytopenia (ITP)
• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w … Recruiting
  2023-507853-13-00 4 2025-02-25 Ulcerative Colitis
• Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN). Recruiting
  2024-514135-17-00 5 2024-11-28 Immunoglobulin A Nephropathy
• Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting
  2023-504231-41-01 10 2024-10-02 Locally advanced or metastatic urothelial cancer
• A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participant … Recruiting
  2023-505678-14-00 4 2024-08-19 Ulcerative Colitis
• CHIP-AML22/Quizartinib sub-study: study of the safety and efficacy of quizartinib in children and adolescents with FLT3-ITD positive AML wit … Recruiting
  2023-505000-27-01 4 2023-12-29 newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML
• Clairleaf TM: A study to test long-term treatment with BI 1291583 in people with bronchiectasis who took part in a previous study with this … Recruiting
  2023-503290-38-00 4 2023-09-05 Bronchiectasis
• Open-label, long-term safety, efficacy, and pharmacokinetics study of vibegron in pediatric subjects 2 years to < 18 years of age with NDO a … Recruiting
  2024-513995-16-00 10 2023-07-28 Neurogenic Detrusor Overactivity (NDO)
• Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting
  2022-500273-14-00 10 2023-07-17 Atherosclerotic cardiovascular disease in patients with ESKD
• Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis Recruiting
  2024-511686-11-00 5 2021-10-05 Multiple Sclerosis in pediatric patients
• A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi … Recruiting
  2025-521546-23-00 5 2026-04-21 Secondary progressive multiple sclerosis
• Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting
  2025-521456-35-00 4 2026-04-13 Mild to moderate asthma
• Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants with Diabetic Macular Edema Recruiting
  2025-522231-34-00 5 2026-03-31 Diabetic Macular Edema
• A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting
  2023-504957-11-00 5 2026-03-24 Metastatic castration resistant prostate cancer
• ROC-101 Safety and Tolerability Study in Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung … Recruiting
  2025-522074-37-00 4 2026-02-19 Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension Associat
• A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascula … Recruiting
  2025-521349-25-00 5 2025-12-09 Macular neovascularization secondary to age-related macular degenerati
• Study to Evaluate Plozasiran in Adults with Hypertriglyceridemia (SHASTA-10 Study) Recruiting
  2024-519712-13-00 5 2025-12-08 Hypertriglyceridemia (HTG)
• A Phase 2b Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Graves' Disease Recruiting
  2025-521920-31-00 4 2025-11-21 Graves’ Disease
• REGN7508 versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults. Recruiting
  2025-520478-20-00 5 2025-11-05 Thromboembolic disease
• EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure … Recruiting
  2025-521188-11-00 5 2025-10-15 Type 2 diabetes
• A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B) Recruiting
  2024-513613-12-00 9 2025-09-18 Part A: Healthy volunteers (Part A is not applicable to the EU; for in
• A Phase 3, placebo-controlled study to investigate LP352 in children and adults with Developmental and Epileptic Encephalopathies Recruiting
  2024-516412-17-00 5 2025-08-26 Developmental and Epileptic Encephalopathies (DEE)

Showing 25–48 of 192 trials